The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis
With multiple approved products,the field of gene therapies has gained substantial momentum over the lastcouple of decades; innovator companies are gradually progressing theirproprietary therapy candidates with cautious optimism
Roots Analysis is pleased toannounce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.
The report features an extensive study of thecurrent market landscape of gene therapies, primarily focusing on geneaugmentation-based therapies, oncolytic viral therapies and genome editingtherapies. The study also features an elaborate discussion on the futurepotential of this evolving market. In addition to other elements, the studyincludes:
§ Adetailed review of the overall landscape of gene therapies and genome editingtherapies.
§ Adiscussion on the various types of viral and non-viral vectors.
§ Aworld map representation, depicting the most active geographies, and a bull’seye analysis, highlighting the distribution of clinical-stage pipelinecandidates by phase of development, type of vector and type of therapy.
§ Adiscussion on the regulatory landscape related to gene therapies across variousgeographies.
§ Detailedprofiles of marketed and phase II/III and gene therapies.
§ Anelaborate discussion on the various commercialization strategies that can beadopted by drug developers for use across different stages of therapydevelopment.
§ Areview of various emerging technologies and therapy development platforms thatare being used to design and manufacture gene therapies.
§ Anin-depth analysis of the various patents that have been filed / granted relatedto gene therapies and genome editing therapies, since 2016.
§ Ananalysis of the various mergers and acquisitions that have taken place in thisdomain, highlighting the trend in the number of companies acquired between2014-2019.
§ Ananalysis of the investments made at various stages of development in companiesthat are focused in this area, between 2014-2019.
§ Ananalysis of the big biopharma players engaged in this domain.
§ Acase study on the prevalent and emerging trends related to vectormanufacturing, with information on companies offering contract services formanufacturing vectors.
§ A discussionon the various operating models adopted by gene therapy developers for supplychain management.
§ Ananalysis of the various factors that are likely to influence the pricing ofgene-based therapies.
§ Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)
§ Key therapeutic areas
§ Autoimmune disorders
§ Cardiovascular diseases
§ Genetic disorders
§ Hematologicaldisorders
§ Metabolic disorders
§ Ophthalmic disorders
§ Oncological disorders
§ Others
§ Type of vector
§ Adeno associatedvirus
§ Adenovirus
§ Herpes simplex virustype 1
§ Lentivirus
§ Plasmid DNA
§ Retrovirus
§ Vaccinia Virus
§ Type of therapy
§ Exvivo
§ Invivo
§ Type of genemodification
§ Gene augmentation
§ Immunotherapy
§ Oncolytic therapy
§ Others
§ Route ofadministration
§ Intraarticular
§ Intracerebellar
§ Intramuscular
§ Intradermal
§ Intravenous
§ Intravitreal
§ Intravesical
§ Subretinal
§ Others
§ Key geographicalregions
§ North America
§ Europe
§ Asia-Pacific
§ Transcripts ofinterviews held with the following senior level representatives of stakeholdercompanies
§ Adam Rogers (CEO, HemeraBiosciences)
§ Al Hawkins (CEO, MiloBiotechnology)
§ Buel Dan Rodgers(Founder & CEO, AAVogen)
§ Cedric Szpirer(Executive & Scientific Director, Delphi Genetics)
§ Christopher Reinhard(CEO and Chairman, Cardium Therapeutics)
§ Ryo Kubota (Chairman,President and Chief Executive Officer, Acucela)
§ Jeffrey Hung (CCO, VigeneBiosciences)
§ Marco Schmeer(Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
§ Michael Triplett(CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
§ Robert Jan Lamers(CEO, Arthrogen)
§ Tom Wilton (ChiefBusiness Officer, LogicBio Therapeutics)
Keycompanies covered in the report
§ Advantagene
§ Advaxis
§ BioMarin
§ bluebird bio
§ FKD Therapies
§ Freeline Therapeutics
§ GenSight Biologics
§ Gradalis
§ InovioPharmaceuticals
§ Marsala Biotech
§ Orchard Therapeutics
§ Pfizer
§ Sarepta Therapeutics
§ Spark Therapeutics
§ Tocagen
§ Transgene
§ uniQure Biopharma
§ VBL Therapeutics
§ ViroMed
Formore information please click on the following link:
OtherRecent Offerings
1. Viral Vectors, Non-Viral Vectors and GeneTherapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV,Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)
2. CAR-T Therapies Market (2ndEdition), 2019-2030
3. Global T-Cell (CAR-T, TCR, and TIL) TherapyMarket (4thEdition), 2019 – 2030
AboutRoots Analysis
RootsAnalysis is one of the fastest growing market research companies, sharing freshand independent perspectives in the bio-pharmaceutical industry. The in-depthresearch, analysis and insights are driven by an experienced leadership teamwhich has gained many years of significant experience in this sector. If you’dlike help with your growing business needs, get in touch atinfo@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
gaurav.chaudhary@rootsanalysis.com
